Clinical Trial Update: Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 trial evaluated omega-3 fatty acids as a personalized treatment approach for major depressive disorder with high inflammation, with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Omega-3 fatty acids (omega-3 fatty acids)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Major Depressive Disorder, Overweight | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2019-11-18